However, the GLP-1 saga turns out, the fact that these drugs have popped up seemingly out of nowhere, and have generated such excitement, highlights the potential existing in the huge repurposed drug (drugs used in another condition than for which they are approved) market for these diseases
58 For all phase 2a, AEs were mild-moderate and GI-related, with no SAEs related to GSBR-1290
Very good product Reply 43 people found this helpful
The office checks the denial reason usually one of a small set and either resubmits with the missing documentation or asks the patient to schedule a follow-up to gather what was missing the first time
It's about more than just following steps
Both medications cause rapid weight loss, so some gallbladder risk exists with both